Schliemann, C., Gerwing, M., Heinzow, H., Harrach, S., Schwöppe, C., Wildgruber, M., . . . Berdel, W. E. (2020). First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. Cancers (Basel).
Citação norma ChicagoSchliemann, Christoph, et al. "First-In-Class CD13-Targeted Tissue Factor TTF-NGR in Patients With Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study." Cancers (Basel) 2020.
MLA CitationSchliemann, Christoph, et al. "First-In-Class CD13-Targeted Tissue Factor TTF-NGR in Patients With Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study." Cancers (Basel) 2020.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.